| Title |
Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
|
|---|---|
| Published in |
Clinical Ophthalmology, April 2017
|
| DOI | 10.2147/opth.s133332 |
| Pubmed ID | |
| Authors |
Noriko Miyamoto, Michiko Mandai, Hiroshi Kojima, Takanori Kameda, Masataka Shimozono, Akihiro Nishida, Yasuo Kurimoto |
| Abstract |
To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months. The measured values of the groups were compared using one-way analysis of variance with Tukey's test to evaluate the difference between baseline and postinjection VA. Among the treatment-naïve eyes, 76% had a good response to aflibercept and 37% of these were aflibercept-dependent, while 58% had a good response to ranibizumab but 51% of these were ranibizumab-dependent. Among the eyes that converted from ranibizumab treatment, 92% of the good responders to ranibizumab with dependence and 76% of the poor responders on ranibizumab had a good response to aflibercept. With aflibercept treatment, the mean VA of treatment-naïve patients was significantly better than the baseline VA over 12 months (P<0.001), and the VA of the converted group improved significantly with proactive treatment and the improvement was continuously maintained from 6 to 12 months. The evaluation of response to and dependence on anti-vascular endothelial growth factor therapies in AMD was useful and practical in managing therapeutic protocols to obtain a good VA. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 21% |
| Student > Bachelor | 3 | 16% |
| Student > Postgraduate | 3 | 16% |
| Researcher | 1 | 5% |
| Other | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 7 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Chemistry | 1 | 5% |
| Materials Science | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 8 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Clinical Ophthalmology
#3,207
of 3,714 outputs
Outputs of similar age
#284,218
of 323,961 outputs
Outputs of similar age from Clinical Ophthalmology
#33
of 41 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,714 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,961 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.